Jung Eun Park

Title: Innovations of Jung Eun Park in Cancer Therapeutics

Introduction

Jung Eun Park is an accomplished inventor based in Bethesda, MD (US). She has made significant contributions to the field of cancer therapeutics through her innovative research and development of novel compounds.

Latest Patents

Jung Eun Park holds a patent for "Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use." This invention provides novel compounds that may serve as anticancer therapeutics. The compounds bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected phosphoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives have achieved both good efficacy and enhanced bioavailability. The invention also includes methods of use, compositions, and kits. Furthermore, it provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents. Jung Eun Park has 1 patent to her name.

Career Highlights

Jung Eun Park is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. Her work focuses on developing innovative solutions to combat cancer, showcasing her dedication to improving patient outcomes through scientific research.

Collaborations

Jung Eun Park has collaborated with notable colleagues, including Wenjian Qian and Christopher C Lai. These collaborations have further enhanced her research and contributed to the advancement of cancer therapeutics.

Conclusion

Jung Eun Park's innovative work in the field of cancer therapeutics exemplifies her commitment to scientific advancement. Her contributions through patents and collaborations highlight her role as a leading inventor in the medical research community.